GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.

Botond Roska

Serge Picaud

Bernard Gilly

Jose Alain Sahel

Luk Vandenberghe

GenSight Biologics S.A.

Beverly Hills Institute of Ophthalmology provides ophthalmology services including LASIK surgery, cataract surgery, and comprehensive eye care. The institute is described as having advanced technology and a team of experienced ophthalmologists.

Beverly Hills Institute of Ophthalmology

APSYS MEDICAL provides advanced technology for ophthalmic surgery.

APSYS MEDICAL

Biotech 365 provides business support services for biotech companies, focusing on fundraising, licensing, and connecting companies with healthcare investors through their global network.

Biotech 365

GenSight Biologics  is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.

Metric
Company Name	GenSight Biologics S.A.	Beverly Hills Institute of Ophthalmology	APSYS MEDICAL	Biotech 365
Symbol	SIGHT
MSH ID	COM:GENSIGHT-BIOLOGICS	COM:90210EYES	COM:APSYS-MEDICAL	COM:BIOTECH-365
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Financial Services & Finance
Industry	Biotechnology	Medical Services	Medical Devices	Biotechnology Business Services
Country	FR	US	FR	FR
Stage
Employee Count	16
Website	gensight-biologics.com	90210eyes.com	apsys-medical.com	biotech-365.com
LinkedIn	gensight-biologics-sa
Founders

Metric
Market Cap	32.79M
Enterprise Value
Monthly Web Traffic		68
Web Traffic Growth		-0.57
Valuation
Raised Capital

Metric
Revenue	3.17M
Revenue (LTM)
Revenue (NTM)
Gross Profit	3.17M
EBITDA	-33.17M
Operating Income	-33.17M
Net Income	-27.67M
EPS	-0.57
Diluted EPS	-0.57
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.95
Operating Profit Margin	-10.12
EBITDA Margin	-10.47
Net Profit Margin	-8.77
Return on Equity	1.65
Return on Assets	-1.34
Return on Capital Employed	20.49

COM:GENSIGHT-BIOLOGICS

GenSight Biologics S.A.

Last Close

0.32

25/11 08:59

Market Cap

31.04M

Beta: -

Volume Today

88.55K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.65
P/B Ratio	-1.18
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	23.08
EV Multiple	-0.36

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding	370.78
Operating Cycle	522.84
Cash Conversion Cycle	-661.19
Asset Turnover	0.49

Metric
Operating Cash Flow	-26.44M
Free Cash Flow	-26.45M
Cash Flow to Debt	-0.74
Operating Cash Flow/Sales	-7.37
Free Cash Flow Yield	-1.34

Metric
Cash & Equivalents	2.25M
Accounts Receivable	-1.06K
Inventory
Goodwill
Debt to Capitalization	-1.45
Debt to Assets	0.49
Current Ratio	1.57
Quick Ratio	0.69

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	-1.30
R&D to Revenue	7.33
SG&A to Revenue	3.10